Shares of Viatris Inc. (VTRS) plummeted over 20% in pre-market trading on Thursday, following the company's release of disappointing fourth-quarter 2024 financial results and weaker-than-expected guidance for 2025.
The pharmaceutical giant reported adjusted earnings per share of $0.54 for Q4 2024, missing analysts' consensus estimate of $0.57 by 5.26%. Additionally, Viatris' quarterly revenue of $3.52 billion fell short of the expected $3.61 billion, marking a year-over-year decline of 8.13%.
The company's 2025 outlook also fell short of market expectations. Viatris forecast 2025 revenue between $13.5 billion and $14 billion, below analysts' estimates of $14.27 billion. Furthermore, the company expects 2025 adjusted earnings per share between $2.12 and $2.26, compared with estimates of $2.59.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。